Engineering and Selecting the Next Generation of Industrial Fungal Chassis. Aspergillus niger serves as the biological engine for a multi-billion dollar industry spanning organic acids, commercial enzymes, and recombinant proteins. CD Biosynsis provides professional Aspergillus niger Strain Development and Screening Services, combining classical microbiology with cutting-edge synthetic biology. Our platform offers a comprehensive "library-to-lead" workflow—from the isolation of high-yielding wild-type strains to the development of hyper-producing industrial chassis with optimized morphology to ensure your production strain is robust and scalable.
Get a Technical QuoteOur strain development platform integrates high-throughput screening technologies with advanced genetic toolkits to accelerate the identification of superior fungal candidates. We focus on bridging the gap between raw isolates and high-performance industrial cell factories.
| Service Tier | Technical Focus | Primary Application | Strategic Value |
|---|---|---|---|
| Wild-type Isolate Screening | Natural biodiversity bioprospecting | Food-grade organic acids | Non-GMO, green-label compliance |
| Hyper-producer Development | Multi-copy integration & dosage | Industrial enzymes (e.g. Amylase) | Maximizes protein secretion titers |
| Morphology Engineering | Filamentous vs. Pellet growth tuning | Submerged fermentation (SmF) | Optimizes oxygen transfer & viscosity |
| Resistance Marker Selection | Antibiotic & Metabolic marker kits | Genetic tool development | Ensures stable high-fidelity integration |
| Chassis Library Construction | Systematic deletion of shunts | "Clean" production hosts | Minimizes byproduct interference |
1. Source Acquisition
2. Initial Screening
3. Morphological Analysis
4. Bioprocess Validation
Collection of environmental isolates or target-specific industrial starter strains for baseline assessment and metabolic flux profiling.
Technical project feasibility study and Mutual NDA signing.
Large-scale agar-based screening using specific substrates or pH-indicators to identify "hot" colonies with high metabolic output.
Selection of candidates based on halo size and acid production rates.
Evaluating growth kinetics and mycelial structure in liquid culture to ensure compatibility with industrial oxygen transfer requirements.
Correlation of pellet vs. mycelial morphology with production efficiency.
Testing top candidates in 5L-50L bioreactors to confirm stability, titer, and yield under commercial-mimicking conditions.
Final delivery of optimized industrial strains and comprehensive characterization dossiers.
We benchmark our selection strategies against landmark fungal research to identify superior industrial candidates.
The demand for non-GMO food additives has driven the search for natural high-performing strains. Technical benchmarks utilized agricultural residues to isolate wild-type A. niger strains. Using Czapek-Dox agar with indicators, researchers identified candidates like the ASP26 strain, which demonstrates superior organic acid secretion without genetic modification, providing a safe, green-label alternative.
(Reference: Bellaouchi et al., 2024)
Achieving high titers for commercial enzymes like glucoamylase necessitates robust selection. Industrial projects have focused on developing genetic toolkits for hyper-producing strains. By deploying systematic screening using high antibiotic concentrations (e.g. G418), researchers identified clones with high-copy integration and maximum activity, essential for building enzyme "super-producers."
(Reference: Liu et al., Biology, 2022)
Mycelial morphology directly dictates oxygen transfer in liquid fermentation. Technical teams have developed chassis strain libraries to study the connection between filamentous growth and submerged macromorphology. By selecting for specific phenotypes, researchers can align the strain’s physical growth with production efficiency, reducing batch variation.
(Reference: Cairns et al., 2022)
Ready to select and engineer a superior industrial fungal chassis?
Contact Us1. How do you distinguish between a standard colony and a high-performance strain?
Initial screening on agar is qualitative. We follow this with quantitative micro-fermentation and 13C-metabolic flux analysis to ensure the high-yield phenotype is robust, stable, and scalable.
2. Can you develop strains that exhibit specific growth morphologies (e.g. pellets)?
Yes. Through morphology engineering and screening, we select for strains that exhibit growth patterns that improve dissolved oxygen levels and lower broth viscosity in industrial fermenters.
3. What is the success rate of finding a commercial-grade wild-type producer?
Commercial-grade natural producers are rare. Our high-throughput screening significantly increases the odds by testing thousands of environmental isolates against specific industrial benchmarks.
4. Are your selection markers compatible with food-safety standards?
Yes. We offer both antibiotic-based markers for early R&D and marker-free/auxotrophic selection systems for final industrial strains to meet global regulatory safety requirements.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.